 Michael Falta
Concepts (225)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Berylliosis | 14 | 2022 | 177 | 2.740 |
Why?
| | CD4-Positive T-Lymphocytes | 23 | 2021 | 965 | 2.230 |
Why?
| | Beryllium | 12 | 2022 | 146 | 2.040 |
Why?
| | HLA-DP beta-Chains | 10 | 2021 | 76 | 1.290 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 10 | 2017 | 309 | 1.070 |
Why?
| | Chemokine CCL3 | 1 | 2021 | 15 | 0.760 |
Why?
| | Chemokine CCL4 | 1 | 2021 | 21 | 0.760 |
Why?
| | Epitopes, T-Lymphocyte | 3 | 2021 | 170 | 0.660 |
Why?
| | Lung | 10 | 2022 | 3546 | 0.580 |
Why?
| | HLA-DP Antigens | 3 | 2010 | 32 | 0.500 |
Why?
| | Lymphocyte Activation | 7 | 2011 | 1044 | 0.430 |
Why?
| | Receptors, Antigen, T-Cell | 5 | 2016 | 618 | 0.410 |
Why?
| | Hypoxanthine Phosphoribosyltransferase | 9 | 2000 | 25 | 0.370 |
Why?
| | Sarcoidosis | 2 | 2022 | 135 | 0.340 |
Why?
| | T-Lymphocytes | 11 | 2016 | 1745 | 0.330 |
Why?
| | Genetic Predisposition to Disease | 5 | 2016 | 2099 | 0.310 |
Why?
| | Chronic Disease | 7 | 2022 | 1590 | 0.290 |
Why?
| | Antibody Affinity | 1 | 2005 | 52 | 0.250 |
Why?
| | Genes, MHC Class II | 1 | 2005 | 70 | 0.250 |
Why?
| | Hybridomas | 4 | 2021 | 230 | 0.240 |
Why?
| | Arthritis, Rheumatoid | 4 | 2005 | 1002 | 0.210 |
Why?
| | Aspergillus nidulans | 1 | 2021 | 5 | 0.190 |
Why?
| | Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 3 | 2007 | 25 | 0.190 |
Why?
| | Mice | 9 | 2021 | 14916 | 0.190 |
Why?
| | Immunity, Innate | 2 | 2021 | 723 | 0.190 |
Why?
| | Mutation | 9 | 2000 | 3350 | 0.190 |
Why?
| | Azathioprine | 1 | 2000 | 49 | 0.170 |
Why?
| | Bronchoalveolar Lavage Fluid | 4 | 2017 | 589 | 0.170 |
Why?
| | Static Electricity | 2 | 2015 | 114 | 0.170 |
Why?
| | Lung Diseases | 3 | 2022 | 696 | 0.170 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2014 | 342 | 0.170 |
Why?
| | Antigens | 1 | 2021 | 318 | 0.170 |
Why?
| | Molecular Sequence Data | 7 | 2015 | 2791 | 0.160 |
Why?
| | Granuloma | 2 | 2022 | 83 | 0.160 |
Why?
| | Mice, Transgenic | 4 | 2021 | 1951 | 0.150 |
Why?
| | Epitope Mapping | 2 | 2015 | 51 | 0.150 |
Why?
| | Animals | 11 | 2021 | 31762 | 0.150 |
Why?
| | Amino Acid Sequence | 6 | 2013 | 1988 | 0.150 |
Why?
| | Humans | 40 | 2022 | 114757 | 0.140 |
Why?
| | Sarcoidosis, Pulmonary | 1 | 2017 | 58 | 0.140 |
Why?
| | T-Lymphocyte Subsets | 1 | 1999 | 384 | 0.140 |
Why?
| | Disease Models, Animal | 3 | 2015 | 3542 | 0.130 |
Why?
| | Peptides | 3 | 2013 | 849 | 0.130 |
Why?
| | Amino Acid Motifs | 1 | 2015 | 198 | 0.120 |
Why?
| | Hypersensitivity | 2 | 2016 | 254 | 0.120 |
Why?
| | Diabetes Mellitus, Type 1 | 2 | 2000 | 3248 | 0.110 |
Why?
| | Peptide Library | 1 | 2013 | 81 | 0.110 |
Why?
| | Clone Cells | 9 | 2005 | 248 | 0.110 |
Why?
| | Pulmonary Emphysema | 2 | 2006 | 268 | 0.110 |
Why?
| | Complementarity Determining Regions | 1 | 2012 | 44 | 0.100 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2012 | 195 | 0.100 |
Why?
| | Chagas Disease | 1 | 2012 | 34 | 0.100 |
Why?
| | Cell Line | 2 | 2016 | 2639 | 0.100 |
Why?
| | Autoantigens | 2 | 2005 | 396 | 0.100 |
Why?
| | Receptors, Cell Surface | 1 | 2013 | 354 | 0.090 |
Why?
| | Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2011 | 12 | 0.090 |
Why?
| | Female | 19 | 2021 | 59507 | 0.090 |
Why?
| | Base Sequence | 6 | 2016 | 2118 | 0.090 |
Why?
| | Male | 17 | 2021 | 55579 | 0.090 |
Why?
| | Gene Expression | 1 | 2015 | 1420 | 0.090 |
Why?
| | Binding Sites | 1 | 2013 | 1176 | 0.090 |
Why?
| | Oligoclonal Bands | 2 | 2007 | 21 | 0.090 |
Why?
| | Colitis, Ulcerative | 1 | 2011 | 105 | 0.090 |
Why?
| | Genes, T-Cell Receptor beta | 2 | 2007 | 18 | 0.080 |
Why?
| | Synovial Fluid | 2 | 2000 | 57 | 0.080 |
Why?
| | Inflammation | 2 | 2022 | 2481 | 0.080 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2007 | 689 | 0.080 |
Why?
| | Autoimmunity | 1 | 2014 | 814 | 0.080 |
Why?
| | Gene Expression Regulation | 2 | 2014 | 2321 | 0.070 |
Why?
| | Crohn Disease | 1 | 2011 | 196 | 0.070 |
Why?
| | Adaptive Immunity | 2 | 2022 | 156 | 0.070 |
Why?
| | Poly I-C | 1 | 2006 | 51 | 0.070 |
Why?
| | Adult | 15 | 2021 | 30548 | 0.070 |
Why?
| | Interferon-beta | 1 | 2006 | 79 | 0.070 |
Why?
| | Fluorescent Antibody Technique | 4 | 2011 | 396 | 0.070 |
Why?
| | Interferon-alpha | 1 | 2006 | 187 | 0.060 |
Why?
| | Breast Neoplasms | 1 | 2016 | 1868 | 0.060 |
Why?
| | Biliary Atresia | 1 | 2007 | 183 | 0.060 |
Why?
| | HLA-DR Antigens | 1 | 2005 | 220 | 0.060 |
Why?
| | Antigen Presentation | 1 | 2005 | 189 | 0.060 |
Why?
| | Biomarkers | 2 | 2011 | 3416 | 0.060 |
Why?
| | Case-Control Studies | 3 | 2021 | 3005 | 0.060 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2006 | 221 | 0.060 |
Why?
| | Enzyme-Linked Immunospot Assay | 2 | 2014 | 34 | 0.050 |
Why?
| | Drug Resistance | 2 | 2000 | 158 | 0.050 |
Why?
| | Middle Aged | 10 | 2021 | 26757 | 0.050 |
Why?
| | Immunoglobulin G | 2 | 2021 | 774 | 0.050 |
Why?
| | Aged | 9 | 2017 | 19094 | 0.050 |
Why?
| | Lactalbumin | 1 | 2001 | 2 | 0.050 |
Why?
| | Antigens, Fungal | 1 | 2021 | 24 | 0.050 |
Why?
| | HLA-DR3 Antigen | 1 | 2021 | 79 | 0.050 |
Why?
| | Forkhead Transcription Factors | 2 | 2014 | 171 | 0.050 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2001 | 72 | 0.050 |
Why?
| | Muramidase | 1 | 2001 | 72 | 0.050 |
Why?
| | Crystallography, X-Ray | 2 | 2014 | 405 | 0.050 |
Why?
| | Fungal Proteins | 1 | 2021 | 119 | 0.050 |
Why?
| | Models, Molecular | 3 | 2014 | 1378 | 0.040 |
Why?
| | Histocompatibility Testing | 2 | 2012 | 118 | 0.040 |
Why?
| | HLA-DR4 Antigen | 1 | 2000 | 76 | 0.040 |
Why?
| | Lymphocyte Subsets | 1 | 2000 | 79 | 0.040 |
Why?
| | Granuloma, Respiratory Tract | 1 | 1999 | 12 | 0.040 |
Why?
| | Interleukin-6 | 1 | 2022 | 675 | 0.040 |
Why?
| | Neoplasm Proteins | 1 | 2001 | 385 | 0.040 |
Why?
| | Mutagenesis, Site-Directed | 2 | 2011 | 345 | 0.040 |
Why?
| | Cloning, Molecular | 1 | 1999 | 524 | 0.040 |
Why?
| | Receptors, Tumor Necrosis Factor, Member 25 | 1 | 2017 | 3 | 0.040 |
Why?
| | Nerve Tissue Proteins | 1 | 2001 | 529 | 0.040 |
Why?
| | Carrier Proteins | 1 | 2001 | 696 | 0.040 |
Why?
| | Interferon-gamma | 2 | 2014 | 722 | 0.040 |
Why?
| | HLA-DRB1 Chains | 1 | 2017 | 98 | 0.040 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2022 | 1134 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 3 | 2012 | 493 | 0.030 |
Why?
| | Emulsions | 1 | 2016 | 42 | 0.030 |
Why?
| | Immunosuppressive Agents | 1 | 2000 | 647 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2000 | 1662 | 0.030 |
Why?
| | Adolescent | 5 | 2007 | 17808 | 0.030 |
Why?
| | Peptide Fragments | 1 | 2000 | 668 | 0.030 |
Why?
| | Polymerase Chain Reaction | 2 | 2016 | 994 | 0.030 |
Why?
| | Protein Structure, Secondary | 2 | 2010 | 325 | 0.030 |
Why?
| | Protein Binding | 2 | 2011 | 1897 | 0.030 |
Why?
| | Alleles | 2 | 2010 | 791 | 0.030 |
Why?
| | Flow Cytometry | 2 | 2014 | 1086 | 0.030 |
Why?
| | Gene Rearrangement, T-Lymphocyte | 1 | 1994 | 13 | 0.030 |
Why?
| | Acute Disease | 1 | 2017 | 912 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2017 | 440 | 0.030 |
Why?
| | Sister Chromatid Exchange | 1 | 1993 | 4 | 0.030 |
Why?
| | Sodium | 1 | 2014 | 182 | 0.030 |
Why?
| | Protein Processing, Post-Translational | 1 | 2016 | 399 | 0.030 |
Why?
| | Chromosome Aberrations | 1 | 1993 | 138 | 0.030 |
Why?
| | Severity of Illness Index | 2 | 2011 | 2539 | 0.030 |
Why?
| | Carcinoma, Hepatocellular | 2 | 1994 | 211 | 0.030 |
Why?
| | Interleukin-2 | 1 | 2014 | 417 | 0.030 |
Why?
| | Spleen | 1 | 2014 | 484 | 0.030 |
Why?
| | Disease Progression | 2 | 2011 | 2387 | 0.030 |
Why?
| | Lymphocytes | 1 | 1993 | 332 | 0.020 |
Why?
| | Radioimmunotherapy | 1 | 1991 | 11 | 0.020 |
Why?
| | Child | 3 | 2000 | 18352 | 0.020 |
Why?
| | Immunophenotyping | 1 | 2012 | 275 | 0.020 |
Why?
| | Chromosome Deletion | 1 | 1991 | 95 | 0.020 |
Why?
| | Granulocytes | 1 | 2011 | 78 | 0.020 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2012 | 353 | 0.020 |
Why?
| | Occupational Exposure | 1 | 1993 | 255 | 0.020 |
Why?
| | Lesch-Nyhan Syndrome | 1 | 1990 | 3 | 0.020 |
Why?
| | Liver Neoplasms | 2 | 1994 | 507 | 0.020 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2011 | 140 | 0.020 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2010 | 66 | 0.020 |
Why?
| | CD3 Complex | 1 | 2010 | 92 | 0.020 |
Why?
| | ROC Curve | 1 | 2011 | 445 | 0.020 |
Why?
| | STAT3 Transcription Factor | 1 | 2011 | 173 | 0.020 |
Why?
| | DNA | 2 | 1993 | 1351 | 0.020 |
Why?
| | Prospective Studies | 1 | 2000 | 6217 | 0.020 |
Why?
| | Cells, Cultured | 3 | 2007 | 3890 | 0.020 |
Why?
| | Down-Regulation | 1 | 2011 | 596 | 0.020 |
Why?
| | Glutamic Acid | 1 | 2010 | 211 | 0.020 |
Why?
| | Bile Ducts, Extrahepatic | 1 | 2007 | 24 | 0.020 |
Why?
| | Phosphorylation | 1 | 2011 | 1571 | 0.020 |
Why?
| | RNA, Messenger | 2 | 2011 | 2557 | 0.020 |
Why?
| | Antibodies, Antinuclear | 1 | 2006 | 60 | 0.020 |
Why?
| | Proteinuria | 1 | 2006 | 77 | 0.020 |
Why?
| | Lupus Nephritis | 1 | 2006 | 52 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2011 | 1796 | 0.020 |
Why?
| | Kidney Glomerulus | 1 | 2006 | 100 | 0.020 |
Why?
| | DNA, Complementary | 1 | 2005 | 257 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2005 | 1013 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 2010 | 1270 | 0.010 |
Why?
| | Prognosis | 1 | 2011 | 3334 | 0.010 |
Why?
| | Antigens, CD | 2 | 2000 | 443 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2010 | 2196 | 0.010 |
Why?
| | Genotype | 1 | 2007 | 1774 | 0.010 |
Why?
| | Fatty Acid-Binding Protein 7 | 1 | 2001 | 3 | 0.010 |
Why?
| | Camelids, New World | 1 | 2001 | 5 | 0.010 |
Why?
| | Colorado | 1 | 2011 | 4086 | 0.010 |
Why?
| | Blotting, Southern | 2 | 1991 | 68 | 0.010 |
Why?
| | Statistics as Topic | 2 | 1993 | 294 | 0.010 |
Why?
| | Fatty Acid-Binding Proteins | 1 | 2001 | 60 | 0.010 |
Why?
| | Chickens | 1 | 2001 | 177 | 0.010 |
Why?
| | Solvents | 1 | 2001 | 105 | 0.010 |
Why?
| | Perforin | 1 | 2000 | 19 | 0.010 |
Why?
| | Pore Forming Cytotoxic Proteins | 1 | 2000 | 15 | 0.010 |
Why?
| | CD28 Antigens | 1 | 2000 | 47 | 0.010 |
Why?
| | Neoplasms | 1 | 1993 | 2105 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2001 | 511 | 0.010 |
Why?
| | Genes, T-Cell Receptor alpha | 1 | 1999 | 11 | 0.010 |
Why?
| | Gene Rearrangement, alpha-Chain T-Cell Antigen Receptor | 1 | 1999 | 21 | 0.010 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2000 | 155 | 0.010 |
Why?
| | Liver | 1 | 2007 | 1631 | 0.010 |
Why?
| | Infant, Newborn | 1 | 1990 | 5035 | 0.010 |
Why?
| | Ligands | 1 | 2001 | 565 | 0.010 |
Why?
| | Sequence Analysis | 1 | 1998 | 35 | 0.010 |
Why?
| | Gene Frequency | 2 | 1990 | 481 | 0.010 |
Why?
| | Temperature | 1 | 2001 | 575 | 0.010 |
Why?
| | Cartilage | 1 | 2000 | 182 | 0.010 |
Why?
| | Fluorescent Dyes | 1 | 2000 | 300 | 0.010 |
Why?
| | Immunologic Memory | 1 | 2000 | 313 | 0.010 |
Why?
| | Membrane Glycoproteins | 1 | 2000 | 429 | 0.010 |
Why?
| | Collagen | 1 | 2000 | 415 | 0.010 |
Why?
| | Computer Simulation | 1 | 2001 | 878 | 0.010 |
Why?
| | Thioguanine | 1 | 1994 | 19 | 0.010 |
Why?
| | Lymphoma, T-Cell | 1 | 1994 | 21 | 0.010 |
Why?
| | Hepatitis | 1 | 1994 | 45 | 0.010 |
Why?
| | Infant | 1 | 2007 | 7935 | 0.010 |
Why?
| | Signal Transduction | 1 | 2006 | 4522 | 0.010 |
Why?
| | Child, Preschool | 1 | 2007 | 9079 | 0.010 |
Why?
| | Rats | 1 | 2001 | 4943 | 0.010 |
Why?
| | Reference Values | 1 | 1994 | 742 | 0.010 |
Why?
| | Twins, Dizygotic | 1 | 1993 | 182 | 0.010 |
Why?
| | Cell Differentiation | 1 | 1998 | 1699 | 0.010 |
Why?
| | Autoimmune Diseases | 1 | 1994 | 391 | 0.010 |
Why?
| | DNA, Neoplasm | 1 | 1991 | 157 | 0.010 |
Why?
| | Aged, 80 and over | 2 | 1993 | 6350 | 0.010 |
Why?
| | Karyotyping | 1 | 1990 | 103 | 0.010 |
Why?
| | Whole-Body Irradiation | 1 | 1990 | 73 | 0.010 |
Why?
| | Genes | 1 | 1990 | 224 | 0.010 |
Why?
| | Ovarian Neoplasms | 1 | 1994 | 388 | 0.010 |
Why?
| | Gene Rearrangement | 1 | 1990 | 138 | 0.010 |
Why?
| | Antigens, Surface | 1 | 1990 | 146 | 0.010 |
Why?
| | Heterozygote | 1 | 1990 | 251 | 0.010 |
Why?
| | Mutagenicity Tests | 1 | 1989 | 9 | 0.010 |
Why?
| | Fetal Blood | 1 | 1990 | 270 | 0.000 |
Why?
| | Sex Factors | 1 | 1993 | 1717 | 0.000 |
Why?
| | Immunotherapy | 1 | 1990 | 475 | 0.000 |
Why?
| | Age Factors | 1 | 1993 | 2890 | 0.000 |
Why?
| | Smoking | 1 | 1993 | 1384 | 0.000 |
Why?
| | Phenotype | 1 | 1990 | 2812 | 0.000 |
Why?
| | Risk Factors | 1 | 1993 | 8627 | 0.000 |
Why?
|
|
Falta's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|